Background: A high percentage of patients treated with anti-TNF agents discontinue therapy. The objective of this analysis was to determine the long-term retention patterns of stable Canadian IBD patients treated with REMICADE® (infliximab [IFX]).
Methods: Using IMS Brogan's™ database of Canadian private and public insurance claims data, our analysis included IBD patients with: (1) first IFX claim between Jan 2008-May 2015; (2) no IFX claims 12 months prior to the initial claim; (3) ≥1 claim for any drug 12 months after the initial IFX claim; and (4) ≥1 claim for any non-IFX drug 4 months after May 2015. Retention was measured at 12-month intervals and unadjusted odds ratios were determined. Within-group analyses compared 12 month retention by number of years on IFX and considered cohorts of patients according to age group, gender and previous biologic experience.
Results: 4,360 patients had ≥2 years of claims history and had been on IFX for ≥1 year. Within-group comparisons showed that the probability of being retained on IFX in subsequent 12 month periods increased with cumulative prior time on IFX. Patients on IFX for 2 to 5 years showed significantly higher retention in the subsequent 12 months compared to patients on IFX for only 1 year (p<0.05). Similar trends were observed across both genders, in patients 19–64 years of age, and for patients who were biologic-naïve.
Conclusions: Real world patients treated with IFX have excellent long-term retention. Previous duration of IFX treatment appears to predict better future retention, becoming statistically significant after 2 years. The results were robust and consistent amongst various subgroups of stable Canadian IBD patients.